Kuros Biosciences (KURN) AI Stock Analysis

• Market Cap: CHF1.06B
• Dividend Yield: N/A
• Average Volume (3M): 128.87K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.45
• Revenue Growth: 104.01%
• EPS Growth: 33.25%
• Country: CH
• Employees: 122
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.05
• Shares Outstanding: 39,175,300
• 10 Day Avg. Volume: 110,510
• 30 Day Avg. Volume: 128,868
• PEG Ratio: 2.90
• Price to Book (P/B): 13.52
• Price to Sales (P/S): 10.51
• P/FCF Ratio: 391.61
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: CHF36.50
• Price Target Upside: 29.62% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): 0.38
• Revenue Forecast (FY): CHF198.30M

• Rating: 61 Neutral
• Price Target: CHF27.00 ▼(-4.12% Downside)
• Action: Reiterated Date: 11/28/25
• Date: Action: Reiterated 11/28/25

The overall stock score of 61 reflects strong financial performance with revenue growth and a solid balance sheet, but is tempered by negative profit margins and valuation concerns due to ongoing losses. Technical indicators show positive momentum, but caution is advised as the stock approaches overbought levels.

Positive Factors

Revenue Growth

A >100% revenue jump demonstrates sustained commercial traction for Kuros's biomaterials across orthopedic and dental channels. This scale expansion supports longer-term market penetration, strengthens distributor leverage, and creates a larger base to absorb fixed costs as the business scales.

High Gross Margin

An 82% gross margin indicates strong product-level economics from proprietary biomaterials. High gross margins provide durable cushion to fund R&D and commercial investment, enabling the company to pursue profitable growth once operating expenses are rationalized.

Improving Cash Generation

Positive operating cash flow and improving free cash flow signal reduced dependence on external financing. This durable improvement enhances financial flexibility to fund commercialization, partnerships, and targeted R&D without immediate capital raises.

Negative Factors

Negative Net Profit Margin

A negative net margin shows the company still posts losses at the bottom line despite revenue growth. Persistent net losses can erode equity and limit retained capital available for reinvestment unless margins improve sustainably through cost control or higher unit economics.

Negative Operating Margins

Negative EBIT/EBITDA indicate core operations remain loss-making, reflecting elevated SG&A or R&D relative to revenue. Structural improvement in operating efficiency or scale is required to convert healthy gross margins into sustainable operating profitability.

Negative Return on Equity

A negative ROE signals capital is not generating shareholder returns, undermining long-term capital efficiency. Even with revenue and cash flow gains, the company must translate growth into positive returns through margin recovery or more productive use of equity capital.

Kuros Biosciences Business Overview & Revenue Model

Company Description

Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development of biopharmaceutical products for tissue repair and bone regeneration in the United States, the European Union, and internationally. It operates through Medical Devices, Pharmaceuticals, and Legacy Portfolio. The company's orthobiologics pipeline products include MagnetOs Granules and MagnetOs Putty in EU and US for the treatment of orthopedics, spinal, and dental problems. Its fibrin/PTH orthobiologics pipeline products comprise KUR-111, which has completed Phase 2b clinical trial for the treatment of tibial plateau fractures; and KUR-113, which completed Phase 2b clinical trial for the treatment of tibial shaft fractures, as well as is in the Phase II trial for the treatment of spinal interbody fusion. The company's sealants pipeline products include Neuroseal EU and US, synthetic tissue sealant for the prevention of cerebrospinal fluid leakage following cranial or spinal surgery. It has collaboration with Checkmate Pharmaceuticals LLC for the development of CYT003 for the treatment of oncology. The company is headquartered in Schlieren, Switzerland.

How the Company Makes Money

Kuros Biosciences generates revenue primarily through the sale of its biomaterial products, including bone graft substitutes and related medical devices. The company's revenue model is built on direct sales to hospitals, clinics, and surgical centers, as well as partnerships with larger medical device companies for distribution. Additionally, Kuros may engage in collaborative research agreements or licensing deals that provide upfront payments and royalties based on future sales of their products. The company's strategic focus on innovation and clinical efficacy, coupled with regulatory approvals from health authorities, further bolsters its market position and contributes to its earnings.

Kuros Biosciences Financial Statement Overview

Summary

Kuros Biosciences shows strong revenue growth and improved cash flows, but faces challenges with negative profit margins and return on equity. The balance sheet is robust with low debt, providing stability.

Income Statement

The company has demonstrated strong revenue growth with a remarkable increase from CHF 33.56 million in 2023 to CHF 75.55 million in 2024. The gross profit margin is healthy at 82.09%. However, the net profit margin remains negative at -4.92%, indicating the company is still incurring losses. The EBIT and EBITDA margins are also negative, reflecting ongoing operational challenges.

Balance Sheet

The balance sheet shows strength with a significant equity base, as indicated by the equity ratio of 69.46%. The debt-to-equity ratio is low at 0.03, suggesting minimal leverage. The return on equity remains negative at -6.32%, reflecting the company's current unprofitability.

Cash Flow

Cash flow from operations has improved significantly, turning positive in 2024 to CHF 3.14 million. The free cash flow also shows a positive trend, indicating better cash management. The free cash flow to net income ratio is positive, suggesting efficient cash conversion despite net losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	107.19M	75.56M	33.56M	17.99M	13.81M	4.04M
Gross Profit	94.89M	62.03M	23.94M	10.77M	10.07M	1.67M
EBITDA	2.13M	-561.00K	-6.84M	-8.84M	-5.29M	-8.58M
Net Income	-6.09M	-3.72M	-13.73M	-14.60M	-7.54M	-11.52M
Balance Sheet
Total Assets	109.97M	84.54M	71.46M	82.95M	91.34M	94.36M
Cash, Cash Equivalents and Short-Term Investments	17.90M	17.46M	14.21M	24.07M	28.62M	28.39M
Total Debt	1.79M	1.79M	2.14M	1.91M	8.93M	2.34M
Total Liabilities	33.32M	25.79M	14.75M	14.09M	14.36M	9.76M
Stockholders Equity	76.65M	58.75M	56.71M	68.86M	76.98M	84.60M
Cash Flow
Free Cash Flow	-787.00K	2.03M	-9.17M	-7.75M	-5.83M	-9.46M
Operating Cash Flow	779.00K	3.14M	-8.84M	-7.35M	-5.45M	-9.24M
Investing Cash Flow	-1.57M	-1.11M	-326.00K	-400.00K	-374.00K	-220.00K
Financing Cash Flow	1.65M	1.34M	-171.00K	3.22M	6.08M	17.08M

Kuros Biosciences Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 28.16
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:KURN, the sentiment is Positive. The current price of 28.16 is above the 20-day moving average (MA) of 25.78, above the 50-day MA of 26.68, and above the 200-day MA of 27.12, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 56.19 is Neutral, neither overbought nor oversold. The STOCH value of 79.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CH:KURN.

Kuros Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BSLN	71 Outperform	CHF665.16M	16.65	―	―	58.51%	―
NWRN	67 Neutral	CHF372.27M	15.53	―	―	744.64%	―
KURN	61 Neutral	CHF1.06B	-167.16	-7.82%	―	104.01%	33.25%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MOLN	48 Neutral	CHF159.08M	-2.43	-49.86%	―	-100.00%	14.45%
SANN	48 Neutral	CHF226.37M	-3.17	-301.13%	―	-56.85%	-186.55%
IDIA	46 Neutral	CHF1.03B	-7.67	―	―	229.23%	63.47%